Skip to main content
SpringerLink
Log in

Efficacy and safety of cilostazol based triple antiplatelet treatment versus dual antiplatelet treatment in patients undergoing coronary stent implantation: an updated meta-analysis of the randomized controlled trials

  • Published:
Journal of Thrombosis and Thrombolysis Aims and scope Submit manuscript

Abstract

The aim of this study was to obtain best estimates of the efficacy and safety of cilostazol-based triple antiplatelet therapy (TAPT: aspirin, clopidogrel and cilostazol) compared with dual antiplatelet therapy (DAPT: aspirin and clopidogrel) in patients undergoing coronary stent implantation. We searched the literature to identify all randomized clinical trials examining efficacy and safety of TAPT versus DAPT in patients undergoing coronary stent implantation. Major efficacy outcomes were death, non-fatal myocardial infarction (MI), ischemic stroke and stent thrombosis (ST) and the safety outcome was bleeding. Data were analyzed using the Review Manager 5.0.0 software. A total of 19 trials involving 7,464 patients were included. TAPT and DAPT were associated with similar rates of death, non-fatal MI, ischemic stroke and ST, but compared with DAPT, TAPT had lower rates of target lesion revascularization (TLR) (RR 0.67, 95 % CI 0.56–0.82, P < 0.0001) and target vessel revascularization (TVR) (RR 0.65, 95 % CI 0.55–0.77, P < 0.00001), as well as less late loss of minimal lumen diameter (mean difference −0.14, 95 % CI −0.17–−0.11, P < 0.00001), and less binary angiographic restenosis (RR 0.54, 95 % CI 0.45–0.65, P < 0.00001). TAPT and DAPT had similar rates of bleeding, but TAPT had significantly higher rates of headache, palpitation, rash and gastrointestinal side-effects. Cilostazol-based TAPT compared with DAPT is associated with improved angiographic outcomes and decreased risk of TLR and TVR but does not reduce major cardiovascular events and is associated with an increase in minor adverse events.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Kushner FG, Hand M, Smith SC Jr, King SB 3rd, Anderson JL et al (2009) 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 54:2205–2241

    Article  PubMed  Google Scholar 

  2. Kuchulakanti PK, Chu WW, Torguson R, Ohlmann P, Rha SW et al (2006) Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents. Circulation 113:1108–1113

    Article  CAS  PubMed  Google Scholar 

  3. Daemen J, Wenaweser P, Tsuchida K, Abrecht L, Vaina S et al (2007) Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 369:667–678

    Article  CAS  PubMed  Google Scholar 

  4. Smit JJ, van’t Hof AW, de Boer MJ, Hoorntje JC, Dambrink JH et al (2006) Incidence and predictors of subacute thrombosis in patients undergoing primary angioplasty for an acute myocardial infarction. Thromb Haemost 96:190–195

    PubMed  Google Scholar 

  5. Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM et al (2005) Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 293:2126–2130

    Article  CAS  PubMed  Google Scholar 

  6. Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS et al (2001) Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 358:527–533

    Article  CAS  PubMed  Google Scholar 

  7. Reaume KT, Regal RE, Dorsch MP (2008) Indications for dual antiplatelet therapy with aspirin and clopidogrel: evidence-based recommendations for use. Ann Pharmacother 42:550–557

    Article  CAS  PubMed  Google Scholar 

  8. Goto S (2005) Cilostazol: potential mechanism of action for antithrombotic effects accompanied by a low rate of bleeding. Atheroscler Suppl 6:3–11

    Article  CAS  PubMed  Google Scholar 

  9. Cone J, Wang S, Tandon N, Fong M, Sun B et al (1999) Comparison of the effects of cilostazol and milrinone on intracellular cAMP levels and cellular function in platelets and cardiac cells. J Cardiovasc Pharmacol 34:497–504

    Article  CAS  PubMed  Google Scholar 

  10. Singh I, Shafiq N, Pandhi P, Reddy S, Pattanaik S et al (2009) Triple antiplatelet therapy vs. dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: an evidence-based approach to answering a clinical query. Br J Clin Pharmacol 68:4–13

    Article  PubMed Central  PubMed  Google Scholar 

  11. Min PK, Jung JH, Ko YG, Choi D, Jang Y et al (2007) Effect of cilostazol on in-stent neointimal hyperplasia after coronary artery stenting: a quantitative coronary angiography and volumetric intravascular ultrasound study. Circ J 71:1685–1690

    Article  CAS  PubMed  Google Scholar 

  12. Lee SW, Park SW, Kim YH, Yun SC, Park DW et al (2007) Comparison of triple versus dual antiplatelet therapy after drug-eluting stent implantation (from the DECLARE-Long trial). Am J Cardiol 100:1103–1108

    Article  CAS  PubMed  Google Scholar 

  13. Lee SW, Park SW, Kim YH, Yun SC, Park DW et al (2008) Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES trial (a randomized comparison of triple antiplatelet therapy with dual antiplatelet therapy after drug-eluting stent implantation in diabetic patients). J Am Coll Cardiol 51:1181–1187

    Article  CAS  PubMed  Google Scholar 

  14. Gao W, Zhang Q, Ge H, Guo Y, Zhou Z (2013) Efficacy and safety of triple antiplatelet therapy in obese patients undergoing stent implantation. Angiology 64:554–558

    Article  CAS  PubMed  Google Scholar 

  15. Youn YJ, Lee JW, Ahn SG, Lee SH, Choi H et al (2014) Multicenter randomized trial of 3-month cilostazol use in addition to dual antiplatelet therapy after biolimus-eluting stent implantation for long or multivessel coronary artery disease. Am Heart J 167:241–248

    Article  CAS  PubMed  Google Scholar 

  16. Douglas JS Jr, Holmes DR Jr, Kereiakes DJ, Grines CL, Block E et al (2005) Coronary stent restenosis in patients treated with cilostazol. Circulation 112:2826–2832

    Article  CAS  PubMed  Google Scholar 

  17. Chen YD, Lu YL, Jin ZN, Yuan F, Lu SZ (2006) A prospective randomized antiplatelet trial of cilostazol versus clopidogrel in patients with bare metal stent. Chin Med J (Engl) 119:360–366

    CAS  Google Scholar 

  18. Lee BK, Lee SW, Park SW, Lee SW, Park DW et al (2007) Effects of triple antiplatelet therapy (aspirin, clopidogrel, and cilostazol) on platelet aggregation and P-selectin expression in patients undergoing coronary artery stent implantation. Am J Cardiol 100:610–614

    Article  CAS  PubMed  Google Scholar 

  19. Kim JY, Lee K, Shin M, Ahn M, Choe H et al (2007) Cilostazol could ameliorate platelet responsiveness to clopidogrel in patients undergoing primary percutaneous coronary intervention. Circ J 71:1867–1872

    Article  PubMed  Google Scholar 

  20. Lu YL, Chen YD, Lu SZ (2007) Effects of intensive antiplatelet therapy in patients with high platelet aggregability after percutaneous coronary intervention. Zhonghua Xin Xue Guan Bing Za Zhi 35:793–796 [in Chinese]

  21. Kum DS, Kim MH, Paik JH, Yu LH, Han J et al (2009) Clinical effects of additional cilostazol administration after drug-eluting stent insertion. Korean Circ J 39:21–25

    Article  CAS  Google Scholar 

  22. Han Y, Li Y, Wang S, Jing Q, Wang Z et al (2009) Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: a randomized, controlled study. Am Heart J 157:733–739

    Article  CAS  PubMed  Google Scholar 

  23. Jeong YH, Hwang JY, Kim IS, Park Y, Hwang SJ et al (2010) Adding cilostazol to dual antiplatelet therapy achieves greater platelet inhibition than high maintenance dose clopidogrel in patients with acute myocardial infarction results of the adjunctive cilostazol versus high maintenance dose clopidogrel in patients with AMI (ACCEL-AMI) study. Circ Cardiovasc Interv 3:17–26

    Article  CAS  PubMed  Google Scholar 

  24. Lee SW, Chun KJ, Park SW, Kim HS, Kim YH et al (2010) Comparison of triple antiplatelet therapy and dual antiplatelet therapy in patients at high risk of restenosis after drug-eluting stent implantation (from the DECLARE-DIABETES and -LONG trials). Am J Cardiol 105:168–173

    Article  CAS  PubMed  Google Scholar 

  25. Ahn CM, Hong SJ, Park JH, Kim JS, Lim DS (2011) Cilostazol reduces the progression of carotid intima-media thickness without increasing the risk of bleeding in patients with acute coronary syndrome during a 2-year follow-up. Heart Vessels 26:502–510

    Article  PubMed  Google Scholar 

  26. Lee SW, Park SW, Kim YH, Yun SC, Park DW et al (2011) A randomized, double-blind, multicenter comparison study of triple antiplatelet therapy with dual antiplatelet therapy to reduce restenosis after drug-eluting stent implantation in long coronary lesions results from the DECLARE-LONG II (drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with long coronary lesions) trial. J Am Coll Cardiol 57:1264–1270

    Article  CAS  PubMed  Google Scholar 

  27. Suh JW, Lee SP, Park KW, Lee HY, Kang HJ et al (2011) Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON ischemic complication after drug-eluting stenT implantation) trial. J Am Coll Cardiol 57:280–289

    Article  CAS  PubMed  Google Scholar 

  28. Lu YL, Pan WQ, Chen DY (2010) Cilostazol improves long-term clinical outcome after stenting in coronary heart disease patients. Chin J Geriatr Heart Brain Vessel Dis 12:690–692 [in Chinese]

  29. Han YL, Su QF, Li Y, Kang J, Yan CH et al (2006) The effects of post coronary stenting triple antiplatelet therapies on platelet functions. Chin J Intern Med 45:635–638 [in Chinese]

  30. Wang SL, Han YL, Jing QM, Wang ZL, Wang DM et al (2005) Long-term effects of cilostazol on clinical outcomes after coronary stent implantation in small-vessel lesions. J Fourth Mil Med Univ 26:994–997 [in Chinese]

  31. Wang SL, Sun F, Zhao X, Chen LL, Feng GB et al (2010) Effect of percutaneous coronary intervention timing and cilostazol use on left ventricular remodeling in patients with non-ST elevation myocardial infarction. Zhonghua Xin Xue Guan Bing Za Zhi 38:870–874 [in Chinese]

  32. Lu YL, Chen YD, Lv SZ, Pan WQ, Liu X (2006) Effect of cilostazol on restenosis in elderly patients with coronary bare-metal stents implantation. Chin J Geriatr 25:537–538 [in Chinese]

  33. Kivela A, Hartikainen J (2006) Restenosis related to percutaneous coronary intervention has been solved? Ann Med 38:173–187

    Article  PubMed  Google Scholar 

  34. Koskinas KC, Chatzizisis YS, Antoniadis AP, Giannoglou GD (2012) Role of endothelial shear stress in stent restenosis and thrombosis pathophysiologic mechanisms and implications for clinical translation. J Am Coll Cardiol 59:1337–1349

    Article  PubMed  Google Scholar 

  35. Morishita R (2005) A scientific rationale for the CREST trial results: evidence for the mechanism of action of cilostazol in restenosis. Atheroscler Suppl 6:41–46

    Article  CAS  PubMed  Google Scholar 

  36. Inoue T, Uchida T, Sakuma M, Imoto Y, Ozeki Y et al (2004) Cilostazol inhibits leukocyte integrin Mac-1, leading to a potential reduction in restenosis after coronary stent implantation. J Am Coll Cardiol 44:1408–1414

    Article  CAS  PubMed  Google Scholar 

  37. Rogers KC, Faircloth JM, Finks SW (2012) Use of cilostazol in percutaneous coronary interventions. Ann Pharmacother 46:839–850

    Article  PubMed  Google Scholar 

  38. Collet JP, Cuisset T, Range G, Cayla G, Elhadad S et al (2012) Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med 367:2100–2109

    Article  CAS  PubMed  Google Scholar 

  39. Price MJ, Berger PB, Teirstein PS, Tanguay JF, Angiolillo DJ et al (2011) Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention the GRAVITAS randomized trial. JAMA 305:1087–1095

    Google Scholar 

  40. Price MJ, Murray SS, Angiolillo DJ, Lillie E, Smith EN et al (2012) Influence of genetic polymorphisms on the effect of high-and standard-dose clopidogrel after percutaneous coronary intervention the GIFT (genotype information and functional testing) study. J Am Coll Cardiol 59:1928–1937

    Article  CAS  PubMed  Google Scholar 

  41. Lee SW, Park SW, Yun SC, Kim YH, Park DW et al (2010) Triple antiplatelet therapy reduces ischemic events after drug-eluting stent implantation: drug-eluting stenting followed by cilostazol treatment REduces Adverse Serious cardiac Events (DECREASE registry). Am Heart J 159:284–291

    Article  CAS  PubMed  Google Scholar 

  42. Sakurai R, Koo BK, Kaneda H, Bonneau HN, Nagai R (2013) Cilostazol added to aspirin and clopidogrel reduces revascularization without increases in major adverse events in patients with drug-eluting stents: a meta-analysis of randomized controlled trials. Int J Cardiol 167:2250–2258

    Article  PubMed  Google Scholar 

  43. Wang P, Zhou SJ, Zhou R, Liu G, Tang P et al (2012) The effectiveness and safety of triple-antiplatelet treatment based on cilostazol for patients receiving percutaneous coronary intervention: a meta-analysis. Clin Cardiol 35:598–604

    Article  PubMed  Google Scholar 

  44. Geng DF, Liu M, Jin DM, Wu W, Deng J et al (2012) Cilostazol-based triple antiplatelet therapy compared to dual antiplatelet therapy in patients with coronary stent implantation: a meta-analysis of 5,821 patients. Cardiology 122:148–157

    Article  CAS  PubMed  Google Scholar 

  45. Jang JS, Jin HY, Seo JS, Yang TH, Kim DK et al (2012) A meta-analysis of randomized controlled trials appraising the efficacy and safety of cilostazol after coronary artery stent implantation. Cardiology 122:133–143

    Article  CAS  PubMed  Google Scholar 

  46. Friedland SN, Eisenberg MJ, Shimony A (2012) Meta-analysis of randomized controlled trials on effect of cilostazol on restenosis rates and outcomes after percutaneous coronary intervention. Am J Cardiol 109:1397–1404

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This work was supported by a grant from the National Natural Science Funding of China (81170181), and a project funded by the Priority Academic Program Development of Jiangsu Higher Education Institutes (PAPD).

Conflict of interests

No conflicts of interest are involved in this manuscript.

Author information

Authors and Affiliations

  1. Department of Cardiology, First Affiliated Hospital of Nanjing Medical University, 300, Guangzhou Road, Nanjing, 210029, China

    Jun Chen, Haoyu Meng, Lei Xu, Jie Liu, Deyu Kong, Pengsheng Chen, Xiaoxuan Gong, Zhijian Yang & Chunjian Li

  2. Department of Epidemiology and Biostatistics, School of Public Health, Nanjing Medical University, Nanjing, China

    Jianling Bai

  3. Department of Chemistry, Northwestern University, Evanston, IL, USA

    Fengwei Zou

  4. Department of Medicine, McMaster University, Hamilton, ON, Canada

    John W. Eikelboom

  5. Department of Cardiology, The Second People’s Hospital of Changzhou City, Changzhou, China

    Jie Liu

Authors
  1. Jun Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Haoyu Meng
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lei Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jie Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Deyu Kong
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Pengsheng Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Xiaoxuan Gong
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Jianling Bai
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Fengwei Zou
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Zhijian Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Chunjian Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. John W. Eikelboom
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Chunjian Li.

Additional information

Dr. Jun Chen, Dr. Haoyu Meng, Dr. Lei Xu and Dr. Jie Liu contributed equally to this work.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chen, J., Meng, H., Xu, L. et al. Efficacy and safety of cilostazol based triple antiplatelet treatment versus dual antiplatelet treatment in patients undergoing coronary stent implantation: an updated meta-analysis of the randomized controlled trials. J Thromb Thrombolysis 39, 23–34 (2015). https://doi.org/10.1007/s11239-014-1090-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11239-014-1090-5

Keywords

Search

Navigation